We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Primary Biliary Cholangitis
MedXY News
EnglishTag

Primary Biliary Cholangitis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis
Gastroenterologycirrhosisliver stiffness measurement

Long-Term Real-World Effectiveness, Safety, and Liver Stiffness Changes with Obeticholic Acid in Primary Biliary Cholangitis

By MedXY|Oct 28, 2025

This study confirms the sustained effectiveness and safety of obeticholic acid (OCA) in primary biliary cholangitis (PBC) over a 2-year median follow-up, highlighting its impact on liver stiffness and fibrosis progression, especially in bio

Liver Stiffness Measurement vs. Biochemical Response in Primary Biliary Cholangitis: Predicting Liver Decompensation with Precision
GastroenterologyBiochemical Responsehepatic decompensation
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Liver Stiffness Measurement vs. Biochemical Response in Primary Biliary Cholangitis: Predicting Liver Decompensation with Precision

By MedXY|Oct 28, 2025

In primary biliary cholangitis, liver stiffness measurement (LSM) outperforms biochemical response in predicting first hepatic decompensation, emphasizing LSM’s pivotal role in clinical risk stratification despite frequent discordance

The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment
GastroenterologyFDAPrimary Biliary Cholangitis

The Withdrawal of OCALIVA: Impact and Implications for Primary Biliary Cholangitis Treatment

By MedXY|Oct 8, 2025

Intercept Pharmaceuticals withdraws OCALIVA from the US market following FDA demands due to safety concerns and lack of proven efficacy in PBC, prompting suspension of related clinical trials and significant shifts in therapeutic landscape.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities